SLC5A2 and heart failure: Sodium–glucose cotransporter-2 (SGLT2) inhibitors (Figure 1) have been shown to reduce the development and progression of heart failure in patients with reduced ejection fraction (HFrEF; EF ≤ 40%), leading to a decrease in the number of cardiovascular deaths and hospitalizations, regardless of patients’ diabetes status (see e.g., DAPA-HF14,15 and EMPEROR-REDUCED16–19) even in previously hospitalized patients (SOLOIST-WHF)20.